Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group.
C GianiR A DenuS LjevarA GronchiA NapolitanoE RosenbaumA SalawuJ BajpaiE A ConnollyA T J LeeJ C TrentH Koseła-PaterczykZ Chia-Chen LiK OguraE PalmeriniG G BaldiA BrunelloF CamposC M CicalaR G MakiA J WagnerV AndelkovicH H LoongD D WongR L JonesW D TapS M TavernaA J LazarE G DemiccoA HongJ V M G BoveeA P Dei TosC D M FletcherD BaumhoerM SbaragliaI M SchaeferR MiceliS StacchiottiPublished in: ESMO open (2024)
In this series, the largest available, metastatic LGFMS, SEF, and H-LGFMS/SEF showed different courses. Systemic agents have modest efficacy, informing future trials of novel agents for these tumours.